Solid Biosciences Inc.: updates and filings

SLDBNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$6.25

November 20, 2026Market cap $944M

What Ploutos Investor adds for Solid Biosciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 73 daysAround Feb 3, 2027 · for Q4 2026

last Nov 3, 2025next Feb 3, 2027

An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 19, 2026 latest annualNov 4, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 6, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Aug 14, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 6, 2026Other material events
    Form8-K
  • Aug 6, 2026Shelf registration for future offerings
    FormS-3ASR
  • Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 6, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 30, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jun 24, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jun 10, 2026Shareholder vote
    Form8-K
  • May 12, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 5, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 23, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 23, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 10, 2026Preliminary proxy statement
    FormPRE 14A
  • Apr 10, 2026Officer or director change
    Form8-K
  • Mar 31, 2026Filing
    FormEFFECT
  • Mar 31, 2026Filing
    FormEFFECT
  • Mar 27, 2026Correspondence with the SEC
    FormCORRESP
  • Mar 27, 2026Correspondence with the SEC
    FormCORRESP
  • Mar 24, 2026Letter from the SEC
    FormUPLOAD

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 4, 2017.

The full analysis

What do Solid Biosciences's filings show?

The filings are where every one of Solid Biosciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.